Close Menu

Prostate Cancer

News and reporting on prostate cancer.

Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.

An Alberta-based research group plans to launch a blood test that could improve the specificity of prostate cancer diagnosis and reduce the number of biopsies.

New data points to strong predictive ability for a ddPCR-based test of AR copy number, while other companies are pursuing tests that target expression of AR splice variants.

The molecular testing firm estimated that more than 70 percent of Medicare patients with prostate cancer will now have coverage for Prolaris.

The data indicates the IsoPSA test could improve on PSA for identifying patients with prostate cancer and distinguishing between low- and high-grade cancers.

A study conducted by Myriad Genetics and Ochsner Clinic showed that Prolaris scores were similar among African-American and non-African-American men. 

The company will return both a genomic prediction of disease aggressiveness and a read on 10-year risks for metastasis and for disease-specific mortality.

The firm's net loss grew year over year and it missed the consensus Wall Street estimates on the top and bottom lines. 

The company missed analyst estimates on the top line but beat the bottom line with growth in prostate cancer and international breast cancer test sales.

The researchers said that they are developing a fiber probe that could generate a Bessel beam that could be inserted into arteries to obtain internal images.